| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 1,016 | 142 | 108 | 1,862 |
| Cost of sales | 207 | 119 | 90 | 514 |
| Research and development | 801 | 700 | 856 | 1,137 |
| Selling, general and administrative | 268 | 230 | 212 | 281 |
| Total operating expenses | 1,276 | 1,049 | 1,158 | 1,932 |
| Loss from operations | -260 | -907 | -1,050 | -70 |
| Interest income | 73 | 81 | 90 | 103 |
| Other income (expense), net | 0 | 8 | -4 | -12 |
| (loss) income before income taxes | -187 | -818 | -964 | 21 |
| Provision for income taxes | 13 | 7 | 7 | 8 |
| Net (loss) income | -200 | -825 | -971 | 13 |
| Basic (in shares) | 390,000,000 | 388,000,000 | 386,000,000 | 385,000,000 |
| Basic (in usd per share) | -0.51 | -2.13 | -2.52 | 0.03 |
| Diluted (in shares) | 390,000,000 | 388,000,000 | 386,000,000 | 399,000,000 |
| Diluted (in usd per share) | -0.51 | -2.13 | -2.52 | 0.03 |
Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA)